You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Learn about the products, people and history that make up our company. All contents © Copyright Johnson & Johnson Services, Inc.1997-2020. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate Interim analysis from Phase 1/2a First-in-Human trial supports further clinical development of investigational vaccine candidate JNJ-78436735 (also known as Ad26.COV2.S) … Johnson & Johnson does not have a direct purchase program available to the general public. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. ジョンソン・エンド・ジョンソングループの総合トップページ。世界の人々の健康と幸せのためにジョンソン・エンド・ジョンソンは、家庭用から医療用まで幅広く、高品質なヘルスケア製品とサービスの提供を通じて、皆様の健康をサポートしています。 EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information, Pharmaceutical Companies of Johnson & Johnson, Advancing New Healthcare Solutions Through Collaboration, Reimagining the Way Healthcare Is Delivered, Learn About the Company's Rich Heritage at Our Digital Museum. The Investor Relations website contains information about Johnson & Johnson's business for stockholders, potential investors, and financial analysts. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. The Investor Relations website contains information about Johnson & Johnson's business for stockholders, potential investors, and financial analysts. For over 130 years, Johnson & Johnson has maintained a tradition of quality and innovation. Johnson & Johnson Medical Devices Companies. Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc. Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI, (This statement was updated on October 4, 2020 to include additional information), This site uses cookies as described in our. Please click below to continue to that site. Contact Us with any questions or Your use of the information on this site is subject to the terms of our Legal Notice. Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Study Here, Johnson & Johnson to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference, Johnson & Johnson Reports 2020 Third-Quarter Results, Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials, Champions of Science: Breaking the Stigma of Mental Illness, Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine Candidate. This site is governed solely by applicable U.S. laws and governmental regulations. All Rights Reserved. Contact Us with any questions or You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Please see our Privacy Policy. Contact Us with any questions or search this site for more information.

You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc.